2. Academic Validation
  3. Small molecule inhibitors of BRAF in clinical trials

Small molecule inhibitors of BRAF in clinical trials

  • Bioorg Med Chem Lett. 2012 Jan 15;22(2):789-92. doi: 10.1016/j.bmcl.2011.11.060.
Alfonso Zambon 1,  Ion Niculescu-Duvaz,  Dan Niculescu-Duvaz,  Richard Marais,  Caroline J Springer
Affiliations

Affiliation

  • 1 The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.
PMID: 22222036 DOI: 10.1016/j.bmcl.2011.11.060
Abstract

Over the last few years, BRaf has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRaf inhibitors, focussing on agents that have been assessed clinically.

Figures